NeuroNOS is developing a novel small-molecule drug for Autism Spectrum Disorder (ASD) and other neurological conditions, based on a technology from the Hebrew University. The therapy is being developed for subcutaneous injection or oral administration and is intended as a treatment for children with autism. Preclinical studies have shown that regulating nitric oxide (NO) levels in the brain produced behavioral and biological improvements in animal models of autism. The company is currently optimizing the drug’s delivery mechanism, with the first phase focused on a subcutaneous injection to ensure optimal bioavailability and patient compliance. NeuroNOS is led by CEO Amir Avniel and is based in Boston, MA. The company recently raised funding to accelerate preclinical development.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2025